SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
Want to see SOPH full AI Analyst Report?
SOPH Stock Chart & Stats
$5.28
-$0.07(-2.14%)
At close: 4:00 PM EST
$5.28
-$0.07(-2.14%)
Day’s Range― - ―
52-Week Range$2.59 - $5.70
Previous CloseN/A
Volume4.05K
Average Volume (3M)100.95K
Market Cap
$342.58M
Enterprise Value$358.96M
Total Cash (Recent Filing)$65.39M
Total Debt (Recent Filing)$62.42M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 11, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding71,668,700
10 Day Avg. Volume137,858
30 Day Avg. Volume100,949
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)6.69
Price to Sales (P/S)4.08
P/FCF Ratio-8.17
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue4.42
Enterprise Value/Gross Profit6.57
Enterprise Value/Ebitda-5.43
Forecast
1Y Price Target
$7.50Price Target Upside42.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.87
Revenue Forecast (FY)$93.40M
Bulls Say, Bears Say
Bulls Say
Revenue & Volume GrowthSustained double‑digit revenue growth and record analysis volumes indicate durable demand for the platform's recurring and usage revenue mix. Higher volumes improve visibility into future consumption, support predictable recurring income, and create scale benefits across software delivery and data insights.
High Adjusted Gross MarginsVery high adjusted gross margins reflect strong unit economics for cloud analytics and sample processing. Durable margin levels support the path to operating leverage as fixed costs are spread across rising volumes, making profitability achievable without dramatic price increases.
Customer Retention & Strategic PartnershipsStrong net dollar retention and low churn show sticky customer relationships and expanding wallet share. Strategic biopharma and cancer‑center partnerships deepen revenue streams, diversify use cases, and strengthen long‑term commercial motion beyond single‑use testing.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow forces reliance on external financing and credit facilities to fund growth and litigation. Continued cash consumption reduces runway, constrains discretionary investments, and increases refinancing or dilution risk if revenue ramps slow.
Large Operating LossesVery wide operating and net losses indicate the cost base substantially exceeds current revenue scale. Until operating leverage meaningfully narrows, profitability remains distant, limiting ability to generate retained earnings and delaying self‑funding of growth initiatives.
Rising Leverage And Balance Sheet StrainIncreased leverage reduces financial flexibility and raises interest and covenant sensitivity as losses persist. A higher debt load limits buffer against market or execution shocks and increases dependence on capital markets or partner funding to sustain investments and litigation defense.
SOPHiA GENETICS News
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $2.59 and its highest was $5.70 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $342.58M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is Aug 11, 2026 which is in 67 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on May 05, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.232 by -$0.038.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.23.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 71,668,700 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.232. Following the earnings report the stock price went down -4.159%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SOPHiA GENETICS Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (42.05% Upside)
$7.50 (42.05% Upside)
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $95.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.40%
12-Months-Change
Fundamentals
Return on Equity
-140.63%
Trailing 12-Months
Asset Growth
7.00%
Trailing 12-Months
Company Description
SOPHiA GENETICS
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
SOPH Company Deck
SOPH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a broadly constructive operational and commercial story: strong top-line growth (22% YoY), record analysis volumes, healthy unit economics (high adjusted gross margin ~75%), improved net dollar retention (117%), and accelerating application and biopharma momentum. Management also took targeted cost actions, expanded liquidity and reaffirmed full-year guidance. Offsetting these positives were higher cash burn, an increased operating loss, FX translation headwinds (Swiss franc up ~14% vs USD), ongoing litigation costs, and softness in Latin America. Growth is expected to be back-half weighted, which introduces execution risk for the year. Overall, the company shows strengthening fundamentals and a clear path toward profitability, but faces near-term cost, FX and legal headwinds that require monitoring.View all SOPH earnings summariesSOPH Stock 12 Month Forecast
Average Price Target
$7.50
▲(42.05% Upside)
Technical Analysis
Schrodinger
―
Zhongchao
―
GeneDx Holdings
―
Definitive Healthcare Corp
―
Omada Health, Inc.
―
Ownership Overview
9.04% Insiders
2.42% Mutual Funds
29.94% Other Institutional Investors
58.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---